2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100613
    MONNA 1572936-83-4 99.79%
    MONNA is a potent transmembrane protein 16A (TMEM16A, Anoctamin-1) blocker with an IC50 of 80 nM. MONNA induces vasorelaxation of rodent resistance arteries in presence or absence of chloride ions.
    MONNA
  • HY-18600A
    Azimilide dihydrochloride 149888-94-8 98.91%
    Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
    Azimilide dihydrochloride
  • HY-N1428R
    Citric acid (standard) 77-92-9
    Citric acid (Standard) is the analytical standard of Citric acid. This product is intended for research and analytical applications. Citric acid is a natural preservative and food tartness enhancer. Citric acid induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Citric acid cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Citric acid causes renal toxicity in mice.
    Citric acid (standard)
  • HY-106591A
    4-Vinylcyclohexene dioxide 106-87-6 ≥98.0%
    4-Vinylcyclohexene dioxide is a metabolite of 4-vinylcyclohexene that can specifically destroy oocytes in primordial and primary follicles of rats and mice. 4-Vinylcyclohexene dioxide induces apoptosis in rat cells is associated with activation of a caspase-mediated cascade.
    4-Vinylcyclohexene dioxide
  • HY-70035
    Otamixaban 193153-04-7 98.25%
    Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban
  • HY-100771
    PCC0208009 1668565-74-9 99.08%
    PCC0208009 is a potent IDO inhibitor with an IC50 value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .
    PCC0208009
  • HY-19321
    PF-06282999 1435467-37-0 99.02%
    PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.
    PF-06282999
  • HY-B0331
    Enalapril 75847-73-3 99.68%
    Enalapril (MK-421) is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research.
    Enalapril
  • HY-100882
    ONO-7300243 638132-34-0 98.46%
    ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
    ONO-7300243
  • HY-106004
    Zamicastat 1080028-80-3 ≥98.0%
    Zamicastat (BIA 5-1058) is a dopamine β-hydroxylase (DBH) inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively. Zamicastat reduces high blood pressure.
    Zamicastat
  • HY-112154
    CXCR7 modulator 2 2227426-37-9 98.71%
    CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a Ki of 13 nM.
    CXCR7 modulator 2
  • HY-112815
    ALK2-IN-2 2254409-25-9 99.93%
    ALK2-IN-2 is an orally active and selective inhibitor of ALK2 (ACVR1), with an IC50 value of 9 nM, and over 700-fold selectivity against ALK3. ALK2-IN-2 can inhibit oxidative stress and protect endothelial cells.
    ALK2-IN-2
  • HY-139577
    Ninerafaxstat 2254741-41-6 99.14%
    Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases.
    Ninerafaxstat
  • HY-159648
    PF-07328948 2936625-34-0 99.88%
    PF-07328948 is an orally effective BDK (branch chain ketoacid dehydrogenase kinase) inhibitor, with IC50 of 110 nM. PF-07328948 acts as a BCKDH (branch chain ketoacid dehydrogenase) enzyme complex degrader to enhance BCAA (branch chain amino acid) catabolism. PF-07328948 improves metabolic and heart failure end points in rats.
    PF-07328948
  • HY-17503AS
    Metoprolol-d7 hydrochloride 1219798-61-4 99.71%
    Metoprolol-d7 (hydrochloride) is the deuterium labeled Metoprolol. Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties[1][2][3][4].
    Metoprolol-d7 hydrochloride
  • HY-19767
    GSK 3008348 1629249-33-7 99.27%
    GSK 3008348 is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for Integrin Antagonist 1 was 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7).
    GSK 3008348
  • HY-P9940
    Emicizumab 1610943-06-0
    Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
    Emicizumab
  • HY-108286
    Talinolol 57460-41-0 99.64%
    Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity.
    Talinolol
  • HY-117290
    BMS-962212 1430114-34-3 99.33%
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity.
    BMS-962212
  • HY-113121S
    Vanillylmandelic acid-d3 74495-70-8 ≥98.0%
    Vanillylmandelic acid-d3 is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM[1].
    Vanillylmandelic acid-d3
Cat. No. Product Name / Synonyms Application Reactivity